JP2002518012A - ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ - Google Patents

ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Info

Publication number
JP2002518012A
JP2002518012A JP2000554854A JP2000554854A JP2002518012A JP 2002518012 A JP2002518012 A JP 2002518012A JP 2000554854 A JP2000554854 A JP 2000554854A JP 2000554854 A JP2000554854 A JP 2000554854A JP 2002518012 A JP2002518012 A JP 2002518012A
Authority
JP
Japan
Prior art keywords
ndv
cdna
protein
virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000554854A
Other languages
English (en)
Japanese (ja)
Inventor
ペトルス ヒューベルツス ペーテルス，ベルナルデュス
レーウ，オラフ スフェン デ
コッフ，フース
レオナルト ヨセフ ヒールケンス，アルナウト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Lelystad Instituut voor Dierhouderij en Diergezondheid BV
Original Assignee
ID Lelystad Instituut voor Dierhouderij en Diergezondheid BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002518012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ID Lelystad Instituut voor Dierhouderij en Diergezondheid BV filed Critical ID Lelystad Instituut voor Dierhouderij en Diergezondheid BV
Publication of JP2002518012A publication Critical patent/JP2002518012A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000554854A 1998-06-19 1999-06-17 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ Withdrawn JP2002518012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202054.7 1998-06-19
EP98202054A EP0974660A1 (en) 1998-06-19 1998-06-19 Newcastle disease virus infectious clones, vaccines and diagnostic assays
PCT/NL1999/000377 WO1999066045A1 (en) 1998-06-19 1999-06-17 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005347888A Division JP2006141398A (ja) 1998-06-19 2005-12-01 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Publications (1)

Publication Number Publication Date
JP2002518012A true JP2002518012A (ja) 2002-06-25

Family

ID=8233832

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000554854A Withdrawn JP2002518012A (ja) 1998-06-19 1999-06-17 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ
JP2005347888A Pending JP2006141398A (ja) 1998-06-19 2005-12-01 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ
JP2009023349A Pending JP2009261387A (ja) 1998-06-19 2009-02-04 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005347888A Pending JP2006141398A (ja) 1998-06-19 2005-12-01 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ
JP2009023349A Pending JP2009261387A (ja) 1998-06-19 2009-02-04 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Country Status (28)

Country Link
US (3) US6719979B2 (enExample)
EP (2) EP0974660A1 (enExample)
JP (3) JP2002518012A (enExample)
KR (1) KR20010053000A (enExample)
CN (2) CN101275142A (enExample)
AR (1) AR020091A1 (enExample)
AT (1) ATE367442T1 (enExample)
AU (1) AU754844B2 (enExample)
BR (1) BR9911383A (enExample)
CA (1) CA2334165A1 (enExample)
CZ (1) CZ300760B6 (enExample)
DE (1) DE69936585T2 (enExample)
DK (1) DK1088077T3 (enExample)
EA (1) EA004796B1 (enExample)
ES (1) ES2291029T3 (enExample)
HR (1) HRP20010042B1 (enExample)
HU (1) HUP0102429A3 (enExample)
ID (1) ID27343A (enExample)
IL (2) IL140381A0 (enExample)
NO (1) NO329193B1 (enExample)
NZ (1) NZ508982A (enExample)
PL (1) PL197722B1 (enExample)
PT (1) PT1088077E (enExample)
SI (1) SI1088077T1 (enExample)
TR (1) TR200100350T2 (enExample)
UA (1) UA77146C2 (enExample)
WO (1) WO1999066045A1 (enExample)
ZA (1) ZA200100241B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512009A (ja) * 1998-09-14 2003-04-02 マウント シナイ スクール オブ メディシン オブ ザ シティー ユニバーシティー オブ ニューヨーク 組換えニューキャッスル病ウイルスｒｎａの発現系およびワクチン
JP2009502204A (ja) * 2005-08-05 2009-01-29 ユニバーシティ オブ マサチューセッツ メディカル スクール パラミクソウイルス用ワクチンとしてのウイルス様粒子
JP2009518007A (ja) * 2005-12-02 2009-05-07 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
JP2013502225A (ja) * 2009-08-21 2013-01-24 メリアル リミテッド 組換えトリパラミクソウイルスワクチン並びに前記の製造および使用方法

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
AU4971500A (en) * 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
EP1074614B1 (en) * 1999-07-27 2004-07-07 Akzo Nobel N.V. A recombinant Newcastle disease virus for in ovo vaccination
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
AU2001263896A1 (en) 2000-06-23 2002-01-14 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
WO2002036617A2 (en) * 2000-11-02 2002-05-10 Akzo Nobel N.V. A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
ATE307606T1 (de) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
EP1485488A4 (en) * 2002-02-21 2005-03-02 Sinai School Medicine RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
KR20060035596A (ko) 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
KR20060029214A (ko) * 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR20090007706A (ko) * 2006-03-15 2009-01-20 인터벳 인터내셔널 비.브이. 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스
AU2007226555B2 (en) * 2006-03-15 2012-07-05 Intervet International B.V. Recombinant Mononegaviral virus vectors
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
HRP20190525T4 (hr) 2011-11-30 2023-01-20 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
SG10202108573TA (en) 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2019227531B2 (en) * 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
CA3106170A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
US11334671B2 (en) * 2019-10-14 2022-05-17 International Business Machines Corporation Adding adversarial robustness to trained machine learning models
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
EP0780475B2 (en) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512009A (ja) * 1998-09-14 2003-04-02 マウント シナイ スクール オブ メディシン オブ ザ シティー ユニバーシティー オブ ニューヨーク 組換えニューキャッスル病ウイルスｒｎａの発現系およびワクチン
JP2009502204A (ja) * 2005-08-05 2009-01-29 ユニバーシティ オブ マサチューセッツ メディカル スクール パラミクソウイルス用ワクチンとしてのウイルス様粒子
JP2009518007A (ja) * 2005-12-02 2009-05-07 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
JP2013502225A (ja) * 2009-08-21 2013-01-24 メリアル リミテッド 組換えトリパラミクソウイルスワクチン並びに前記の製造および使用方法

Also Published As

Publication number Publication date
WO1999066045A1 (en) 1999-12-23
EP1088077B2 (en) 2012-03-21
SI1088077T1 (sl) 2008-02-29
JP2006141398A (ja) 2006-06-08
CZ300760B6 (cs) 2009-08-05
HUP0102429A3 (en) 2003-12-29
AU754844B2 (en) 2002-11-28
IL140381A (en) 2008-06-05
TR200100350T2 (tr) 2001-06-21
DE69936585T2 (de) 2008-04-30
PL348300A1 (en) 2002-05-20
EP0974660A1 (en) 2000-01-26
NO20006406D0 (no) 2000-12-15
CN1314942A (zh) 2001-09-26
AU4399199A (en) 2000-01-05
NZ508982A (en) 2003-07-25
NO329193B1 (no) 2010-09-13
DK1088077T3 (da) 2007-11-12
KR20010053000A (ko) 2001-06-25
UA77146C2 (en) 2006-11-15
US6719979B2 (en) 2004-04-13
IL140381A0 (en) 2002-02-10
ZA200100241B (en) 2002-06-26
HUP0102429A2 (hu) 2001-10-28
ATE367442T1 (de) 2007-08-15
EA004796B1 (ru) 2004-08-26
US20040234552A1 (en) 2004-11-25
CA2334165A1 (en) 1999-12-23
HRP20010042B1 (en) 2011-03-31
ID27343A (id) 2001-04-05
US7547442B2 (en) 2009-06-16
DE69936585D1 (de) 2007-08-30
HRP20010042A2 (en) 2001-12-31
NO20006406L (no) 2001-02-19
ES2291029T3 (es) 2008-02-16
EA200100057A1 (ru) 2001-08-27
BR9911383A (pt) 2001-03-13
JP2009261387A (ja) 2009-11-12
AR020091A1 (es) 2002-04-10
US20030087417A1 (en) 2003-05-08
CN101275142A (zh) 2008-10-01
PT1088077E (pt) 2007-10-29
CZ20004707A3 (en) 2001-05-16
EP1088077A1 (en) 2001-04-04
US20040235134A1 (en) 2004-11-25
EP1088077B1 (en) 2007-07-18
US7332169B2 (en) 2008-02-19
PL197722B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
US7332169B2 (en) Newcastle disease virus infectious clones, vaccines and new diagnostic assays
US9476033B2 (en) Recombinant newcastle disease viruses useful as vaccines or vaccine vectors
KR19990063811A (ko) 클론된 뉴클레오타이드 서열로부터 감염성 호흡장애 바이러스의생산 방법
MXPA01002656A (es) Sistema de expresion del rna de virus de la enfermedad de newcastle, recombinante y vacunas.
KR20090007706A (ko) 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스
MX2008011727A (es) Vectores de virus mononegaviral recombinantes.
JPH11507241A (ja) 組換え鶏痘ウイルスおよびその使用
RU2441070C2 (ru) Рекомбинантный вирус болезни ньюкастла, экспрессирующий н5 гемаглютинин вируса птичьего гриппа (avian ineluenza)
AU775514B2 (en) A recombinant Newcastle Disease virus as an embryo vaccine
CN101426917A (zh) 重组单股反链病毒目病毒载体
MXPA00012787A (en) Newcastle disease virus infectious clones, vaccines and diagnostic assays
EP1074614B1 (en) A recombinant Newcastle disease virus for in ovo vaccination
Liu Generating a new vaccine for protecting poultry from Newcastle disease and controlling viral shedding
BRPI0709602B1 (pt) Vetor de vírus mononegavirales recombinante, e, vacina contra um patógeno microbiano

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20010413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050307

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20050307

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20050310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050805

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20051206